CD8A and relapsing-remitting multiple sclerosis: We next tested the impact of DHODH inhibition on the patrolling properties of EM and TEMRA CD8 T cells of with RRMS, two CD8 T cell subsets in which predominant T cell clones were notable among CNS lesions, CSF, and blood CD8+ T cells were found (15).